文献速递传染病防控与疫情报告免疫规划

肠道病毒D68相关急性呼吸道疾病——美国新疫苗监测网络,2018年7月至2020年11月

Enterovirus D68-Associated Acute Respiratory Illness ─ New Vaccine Surveillance Network, United States, July-November 2018-2020.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-11-26

肠道病毒D68(EV-D68)可引起轻至重度急性呼吸道疾病(ARI)和急性弛缓性脊髓炎(AFM)。美国新疫苗监测网络(NVSN)在7家医疗中心对18岁以下ARI患者开展监测,2018年报告382例EV-D68检出,2019年降至6例,2020年为30例;2020年检出者中22例(73%)为非西班牙裔黑人。2020年检出数低于基于2014年以来双年周期模式的预期,可能受COVID-19防控措施影响,未来趋势未知,需持续监测。

要点

  • 2018年NVSN报告382例18岁以下ARI患者EV-D68检出,2019年降至6例,2020年为30例。
  • 2020年30例EV-D68检出中22例(73%)为非西班牙裔黑人。
  • 2020年检出数低于基于2014年以来双年周期模式的预期,可能受COVID-19防控措施影响。

核心结论

  • 2020年EV-D68检出数低于基于2014年以来双年周期模式的预期,可能受广泛COVID-19防控措施限制,行为改变对未来流行时间和水平的影响未知,需持续监测。

研究设计与样本

  • 美国新疫苗监测网络(NVSN)在7家美国医疗中心对18岁以下因ARI就诊于急诊或住院的患者呼吸道标本进行EV-D68检测,总结2018年、2019年和2020年7月至11月的检出情况并描述患者人口学和临床特征。

主要发现

  • 2018年NVSN报告18岁以下ARI患者呼吸道标本EV-D68检出382例,2019年降至6例,2020年为30例。
  • 2020年18岁以下EV-D68检出患者中22例(73%)为非西班牙裔黑人。
  • 2014年至2018年美国观察到EV-D68双年周期模式,2020年检出数低于基于该模式的预期。

局限性

  • 2020年EV-D68循环可能受广泛COVID-19防控措施限制,行为改变对未来年份流行时间和水平的影响未知。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enterovirus D68 (EV-D68) is associated with a broad spectrum of illnesses, including mild to severe acute respiratory illness (ARI) and acute flaccid myelitis (AFM). Enteroviruses, including EV-D68, are typically detected in the United States during late summer through fall, with year-to-year fluctuations. Before 2014, EV-D68 was infrequently reported to CDC (1). However, numbers of EV-D68 detection have increased in recent years, with a biennial pattern observed during 2014-2018 in the United States, after the expansion of surveillance and wider availability of molecular testing. In 2014, a national outbreak of EV-D68 was detected (2). EV-D68 was also reported in 2016 via local (3) and passive national (4) surveillance. EV-D68 detections were limited in 2017, but substantial circulation was observed in 2018 (5). To assess recent levels of circulation, EV-D68 detections in respiratory specimens collected from patients aged <18 years* with ARI evaluated in emergency departments (EDs) or admitted to one of seven U.S. medical centers† within the New Vaccine Surveillance Network (NVSN) were summarized. This report provides a provisional description of EV-D68 detections during July-November in 2018, 2019 and 2020, and describes the demographic and clinical characteristics of these patients. In 2018, a total of 382 EV-D68 detections in respiratory specimens obtained from patients aged <18 years with ARI were reported by NVSN; the number decreased to six detections in 2019 and 30 in 2020. Among patients aged <18 years with EV-D68 in 2020, 22 (73%) were non-Hispanic Black (Black) persons. EV-D68 detections in 2020 were lower than anticipated based on the biennial circulation pattern observed since 2014. The circulation of EV-D68 in 2020 might have been limited by widespread COVID-19 mitigation measures; how these changes in behavior might influence the timing and levels of circulation in future years is unknown. Ongoing monitoring of EV-D68 detections is warranted for preparedness for EV-D68-associated ARI and AFM.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Shah MM, Perez A, Lively JY, et al. Enterovirus D68-Associated Acute Respiratory Illness ─ New Vaccine Surveillance Network, United States, July-November 2018-2020. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34818320. doi:10.15585/mmwr.mm7047a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。